Summary of Literature for Ertapenem (Invanz)

Study Solomkin et al. Annals of Surgery

Comparison Groups A. Ertapenem 1 g once a day B. Piperacillin / Tazobactam given 3.375 g every 6 hours (Study therapies were given for a minimum of 4 days and maximum of 14 days)

Objective Compare the clinical efficacy and safety of ertapenem Versus Piperacillin / Tazobactam in the Treatment of Complicated Intraabdominal Infections ( perforated or abscessed appendicitis were most common) Compare Ertapenem to Cefotetan for prophylaxis in elective colorectal surgery and appendectomy

Outcomes The efficacy of Ertapenem was equivalent To Piperacillin / Tazobactam in the treatment of the Intraabdominal infections Similar safety and tolerability profile of both groups Ertapenem may be a useful option that could eliminate the need for combination and/or multidosed antibiotic regimens for the empiric treatment of intra-abdominal infections

Itani et al. The New England Journal of Medicine

A. Single dose of 1 gm of Ertapenem B. 2 gm of Cefotetan (Both infused over a 30-minute period within 60 minutes before the initial surgical incision) Group A: Ertapenem (1 g/day) for 3 days Group B: Ertapenem (1 g/day) for 5 days (To achieve balance between the treatment groups, patients

Prophylaxis with Ertapenem was superior to prophylaxis with Cefotetan Primary efficacy end point was the proportion of patients for whom prophylaxis was successful at the 4-week follow-up assessment after treatment

Basoli et al. Journal of Gastrointestinal Surgery

To compare Ertapenem 3 days vs. 5 Days in CommunityAcquired Intraabdominal Infection.

3 days of Ertapenem had the same clinical and bacteriological efficacy as a standard duration (5 days) of Ertapenem for the treatment of the Localized Community Acquired Intraabdominal Infections Shorter duration of treatment can have positive impact on bacterial resistance and cost of the

Yellin et al. International Journal of Antimicrobial Agents

were stratified according to the site of infection (complicated appendicitis vs. all other diagnoses) Group A: Ertapenem IV 1 g once a day Group B: Ertapenem IV 1.5 g once a day Group C: Ceftriaxone IV 2 g once a day plus Metronidazole IV 500 mg every 8 hours (Primary cause of infections was appendicitis)

health care Larger trials are required to substantiate the findings Response rates were: 84% (Group A) versus 85% (Group C1) and 83% (Group B) versus 77% (Group C2). Ertapenem had a favorable dosing schedule and was as effective as the combination of Ceftriaxone plus Metronidazole in the therapy of intraabdominal infections

To compare Ertapenem monotherapy to combination therapy with Ceftriaxone plus Metronidazole for treatment of complicated intraabdominal infections